Management of cerebral venous thrombosis in Spain: MOTIVATE descriptive study.
Manejo de la trombosis venosa cerebral en España: estudio descriptivo MOTIVATE.
Anticoagulación
Anticoagulation
Cefalea
Cerebral venous thrombosis
Endovascular treatment
Headache
Papiledema
Papilloedema
Terapia endovascular
Thrombophilia
Trombofilia
Trombosis venosa cerebral
Journal
Neurologia
ISSN: 2173-5808
Titre abrégé: Neurologia (Engl Ed)
Pays: Spain
ID NLM: 101778590
Informations de publication
Date de publication:
09 Sep 2021
09 Sep 2021
Historique:
received:
19
03
2021
revised:
29
04
2021
accepted:
22
05
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
aheadofprint
Résumé
Cerebral venous thrombosis (CVT) is an uncommon cause of stroke that mainly affects young adults. Early, accurate diagnosis can reduce the rate and severity of complications. The aim of this study was to analyse the clinical characteristics, management, and treatment of CVT in different centres in Spain. We conducted a multicentre, retrospective, descriptive study of patients hospitalised due to CVT between 2008 and 2017 at 11 Spanish centres. We included 256 patients, with a mean age (SD) of 49.8 (18.7) years; 51% of patients were women. The most frequent symptoms were headache (73%), focal deficits (50%), epileptic seizures (33%), and encephalopathy (21%). The most frequent localisations were the superior sagittal sinus (12.5%), the transverse sinus (10.9%), and 2 or more sinuses or veins (66.4%). Thrombophilia was the most frequent known aetiology (24%), and was most commonly associated with the prothrombin G20210A mutation (19%). Forty-six percent of patients were treated with antithrombotics for 3-6 months, 21% for one year, and 22.6% required indefinite anticoagulation. Endovascular therapy was performed in 5% of cases, and 33% required neurosurgery. Regarding outcomes, 75% of patients were independent at 3 months (modified Rankin Scale [mRS] score ≤ 2), with papilloedema (P=.03), focal deficits (P=.001), and encephalopathy (P <.001) showing a statistically significant association with poor prognosis (mRS> 3). The in-hospital mortality rate was 4.3%, with a 3-month mortality rate of 6.3%. The diverse risk factors and variable presentation of CVT represent a challenge in the diagnosis and treatment of this condition. To improve prognosis and reduce mortality, it is essential to establish management protocols for this entity.
Identifiants
pubmed: 34511275
pii: S0213-4853(21)00116-X
doi: 10.1016/j.nrl.2021.05.016
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Informations de copyright
Copyright © 2021 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.